Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B

Hoffmann-La Roche820 enrolled

Overview

The purpose of this study is to determine the safety and efficacy of Pegasys + placebo + lamivudine versus lamivudine alone in patients with lamivudine versus lamivudine alone in patients with hepatitis B antigen CHB.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Enrollment

820

Conditions

Chronic Hepatitis B

Interventions

PEGASYSDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnosis of hepatitis B * Not pregnant Exclusion Criteria: * Treatment for hepatitis B in past 6 months * Other hepatitis infections * Severe liver disease * Pregnancy

Locations (74)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Unnamed facility

Scottsdale, Arizona, United States

Unnamed facility

Downey, California, United States

Unnamed facility

Los Angeles, California, United States

Unnamed facility

Pasadena, California, United States

Unnamed facility

San Francisco, California, United States

Unnamed facility

Atlanta, Georgia, United States

Unnamed facility

Honolulu, Hawaii, United States

Unnamed facility

Boston, Massachusetts, United States

Unnamed facility

Ann Arbor, Michigan, United States

Unnamed facility

Minneapolis, Minnesota, United States

...and 64 more locations